HC Wainwright Forecasts LifeMD's Q2 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of LifeMD in a report released on Wednesday, May 7th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.02 for the quarter, down from their prior estimate of $0.03. HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD's Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.16 EPS and Q4 2026 earnings at $0.22 EPS.

Other equities analysts also recently issued research reports about the company. B. Riley upgraded LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $11.00.

LifeMD Price Performance

LifeMD stock traded down $0.03 during trading on Monday, reaching $8.52. 1,542,901 shares of the company were exchanged, compared to its average volume of 931,779. LifeMD has a 52-week low of $3.99 and a 52-week high of $9.80. The company has a market capitalization of $387.22 million, a P/E ratio of -13.31 and a beta of 2.22. The stock's 50 day simple moving average is $5.93 and its two-hundred day simple moving average is $5.73.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to analysts' expectations of $62.47 million.

Institutional Trading of LifeMD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LFMD. Barclays PLC grew its stake in LifeMD by 311.7% during the third quarter. Barclays PLC now owns 49,017 shares of the company's stock worth $257,000 after buying an additional 37,112 shares during the period. JPMorgan Chase & Co. grew its stake in LifeMD by 496.4% during the third quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company's stock worth $462,000 after buying an additional 73,389 shares during the period. Mirador Capital Partners LP grew its stake in LifeMD by 139.3% during the fourth quarter. Mirador Capital Partners LP now owns 106,059 shares of the company's stock worth $525,000 after buying an additional 61,731 shares during the period. Magnus Financial Group LLC grew its stake in LifeMD by 31.1% during the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company's stock worth $79,000 after buying an additional 3,792 shares during the period. Finally, Rhumbline Advisers grew its stake in LifeMD by 6.1% during the fourth quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock worth $241,000 after buying an additional 2,814 shares during the period. Hedge funds and other institutional investors own 35.52% of the company's stock.

Insider Activity at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $7.78, for a total transaction of $389,000.00. Following the completion of the sale, the chief executive officer now owns 2,575,721 shares in the company, valued at $20,039,109.38. This represents a 1.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 151,995 shares of company stock worth $1,101,922 in the last three months. Insiders own 15.97% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.